Nassim Kamar
Advanced in Hereditary Neuralgic Amyotrophy

Nassim Kamar

CHU Toulouse Rangueil
Toulouse, FR 
Advanced in Hereditary Neuralgic Amyotrophy
CHU Toulouse Rangueil
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Nassim Kamar practices in Toulouse, France. Mr. Kamar is rated as an Advanced expert by MediFind in the treatment of Hereditary Neuralgic Amyotrophy. His top areas of expertise are Hepatitis E, Hepatitis, Cytomegalovirus Infection, Kidney Transplant, and Liver Transplant.

His clinical research consists of co-authoring 567 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Hereditary Neuralgic Amyotrophy.

Gender
Male

Locations

CHU Toulouse Rangueil
Toulouse, 31400, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Evaluation of a Strategy Based on the 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation: the I4BiS Study
Evaluation of a Strategy Based on the 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation: the I4BiS Study
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Other, Drug
Study Drug: Corticosteroid boluses Methylprednisolone
Study Phase: Phase 3
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial
Enrollment Status: Terminated
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drug: L-Carnitine
Study Phase: Phase 3
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Enrollment Status: Terminated
Publish Date: July 23, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 3
Evaluation of 2 Techniques of Apheresis to Desensitize ABO Incompatible Kidney Transplant Candidates: Double Filtration PlasmaPheresis (DFPP) vs Large Plasma Volume Specific ImmunoAdsorption
Evaluation of 2 Techniques of Apheresis to Desensitize ABO Incompatible Kidney Transplant Candidates: Double Filtration PlasmaPheresis (DFPP) vs Large Plasma Volume Specific ImmunoAdsorption
Enrollment Status: Completed
Publish Date: April 12, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
Specialized Proresolving Mediators Evaluation in Pneumocystis Pneumonia Human Infection : Pilot Study.
Specialized Proresolving Mediators Evaluation in Pneumocystis Pneumonia Human Infection : Pilot Study.
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
Impact of a Simple Clinical Tool for Increasing Enrollment on a Kidney Transplant Waiting List for Patients Aged Over 70 and Initiating Dialysis
Impact of a Simple Clinical Tool for Increasing Enrollment on a Kidney Transplant Waiting List for Patients Aged Over 70 and Initiating Dialysis
Enrollment Status: Terminated
Publish Date: March 04, 2021
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
Enrollment Status: Terminated
Publish Date: July 13, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
The Bacteriuria in Renal Transplantation (BiRT) Study: A Prospective, Randomized, Parallel-group, Multicenter, Open-label, Superiority Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria
The Bacteriuria in Renal Transplantation (BiRT) Study: A Prospective, Randomized, Parallel-group, Multicenter, Open-label, Superiority Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria
Enrollment Status: Completed
Publish Date: July 18, 2019
Intervention Type: Other
Study Phase: Phase 4
View 8 Less Clinical Trials

567 Total Publications

Kidney Transplant Recipients Switching to Prolonged-Release Tacrolimus: Five-Year Real-World Clinical Outcomes From the CHORUS Study
Kidney Transplant Recipients Switching to Prolonged-Release Tacrolimus: Five-Year Real-World Clinical Outcomes From the CHORUS Study
Journal: Annals of transplantation
Published: June 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kamar's expertise for a condition
ConditionClose
View All 21 Advanced Conditions
View All 76 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile